SCHEMBL1608248

SCHEMBL1608248

CN(C)c1ccc(-c2cc(-c3cnc4[nH]cnc4c3)n[nH]2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 1/20 0.46
CCNB2 O95067 1/20 0.44
CDK1 P06493 1/20 0.44
CCNB1 P14635 1/20 0.44
GSK3A P49840 1/20 0.44
GSK3B P49841 1/20 0.44
CCNB3 Q8WWL7 1/20 0.44
HPGDS O60760 1/20 0.40
TNIK Q9UKE5 2/20 0.39
RAB9A P51151 3/20 0.39
NPC1 O15118 2/20 0.39
MAPT P10636 1/20 0.39
MAPK1 P28482 1/20 0.39
MAPK8 P45983 1/20 0.37
MAPK9 P45984 1/20 0.37
MAPK10 P53779 1/20 0.37
POLB P06746 1/20 0.37
IP6K1 Q92551 1/20 0.36
TDP1 Q9NUW8 1/20 0.35
MEN1 O00255 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1250263 0.84 APP (0.46) APPCCNB2CDK1CCNB1GSK3A
SCHEMBL1248625 0.81 APP (0.46) APPCDK1GSK3BHPGDSTNIK
SCHEMBL1607485 0.75 APP (0.45) APPCCNB2CDK1CCNB1GSK3A
SCHEMBL12573247 0.74 APP (0.52) APPTNIKRAB9ANPC1MAPT
SCHEMBL1608493 0.73 APP (0.46) APPCCNB2CDK1CCNB1GSK3A
SCHEMBL1251984 0.72 APP (0.54) APPCCNB2CDK1CCNB1GSK3A
SCHEMBL31063702 0.72 APP (0.47) APPCCNB2CDK1CCNB1GSK3A
SCHEMBL1251703 0.72 APP (0.52) APPRAB9ANPC1MAPTMAPK1
SCHEMBL1249681 0.72 TNIK (0.55) APPTNIKRAB9ANPC1MAPT
SCHEMBL1608233 0.72 APP (0.44) APPCCNB2CDK1CCNB1GSK3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110081297-A1 Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles MERCK & CO. INC. 2011-04-07 US claimed
US-20110081297-A1 Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles MERCK & CO. INC. 2011-04-07 US disclosed
US-20110081297-A1 Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles MERCK & CO. INC. 2011-04-07 US disclosed
US-20110081297-A1 Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles MERCK & CO. INC. 2011-04-07 US disclosed
WO-2009146343-A1 NOVEL SUBSTITUTED PYRAZOLES, 1,2,4-OXADIAZOLES, AND 1,3,4-OXADIAZOLES MERCK & CO., INC. (US) 2009-12-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110081297-A1 Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles APP, PSEN1, BACE1 APP 1/4885CCNB2 4087/4885CDK1 2989/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.